Verve Therapeutics (Verve Therapeutics) Cash-to-Debt : 8.23 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Verve Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Verve Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 8.23.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Verve Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Verve Therapeutics's Cash-to-Debt or its related term are showing as below:

VERV' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.94 Med: 157.19 Max: No Debt
Current: 8.23

During the past 5 years, Verve Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 5.94. And the median was 157.19.

VERV's Cash-to-Debt is ranked better than
52.83% of 1539 companies
in the Biotechnology industry
Industry Median: 6.49 vs VERV: 8.23

Verve Therapeutics Cash-to-Debt Historical Data

The historical data trend for Verve Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Verve Therapeutics Cash-to-Debt Chart

Verve Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

184.37

6.77

8.33

Verve Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial													6.35	5.94	6.32	8.33	8.23

Competitive Comparison of Verve Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Verve Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Verve Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verve Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Verve Therapeutics's Cash-to-Debt falls into.

Verve Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Verve Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	623.95	/	(10.192	+	64.715)
	=	8.33

Verve Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	606.367	/	(10.22	+	63.454)
	=	8.23

Verve Therapeutics (NAS:VERV) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Verve Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Verve Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Verve Therapeutics (Verve Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verve Therapeutics Inc (NAS:VERV) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Brookline Avenue, Suite 601, Boston, MA, USA, 02215

Website

https://www.vervetx.com

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Executives

Krishna Yeshwant	director, 10 percent owner	C/O GOOGLE VENTURES 2011, L.P., 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Allison Dorval	officer: Chief Financial Officer	C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Fred T. Fiedorek	officer: Chief Medical Officer	55 BALDWIN LANE, PRINCETON NJ 08540
Joan Nickerson	officer: Chief Administrative Officer	C/O VERVE THERAPEUTICS, INC., 201 BROOKLINE AVENUE, SUITE 601, BOSTON MA 02215
Andrew Bellinger	officer: Chief Scientific Officer	500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Gv 2017 Gp, L.l.c.	10 percent owner	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc.	other: Member of 10% Group	1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Sekar Kathiresan	director, 10 percent owner, officer: Chief Executive Officer	500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Lonnel Coats	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
Alexander Cumbo	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Burt A Adelman	director, 10 percent owner	DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Andrew D. Ashe	officer: See Remarks	C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Logos Global Management Lp	10 percent owner	1 LETTERMAN DRIVE, BLDG C, SUITE C3-350, SAN FRANCISCO CA 94129
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116